A Voice From the Past: Rediscovering the Virchow Node With Prostate-specific Membrane Antigen-targeted 18F-DCFPyL Positron Emission Tomography Imaging - 18/06/18
Doi : 10.1016/j.urology.2018.03.030
Rudolf A. Werner a, b, Christian Andree c, Mehrbod S. Javadi a, Constantin Lapa b, Andreas K. Buck b, Takahiro Higuchi b, d, Martin G. Pomper a, e, Michael A. Gorin a, e, Steven P. Rowe a, e, * 
, Kenneth J. Pienta e
, Kenneth J. Pienta e a Division of Nuclear Medicine and Molecular Imaging, The Russell H. Morgan Department of Radiology and Radiological Science, Johns Hopkins University School of Medicine, Baltimore, MD
b Department of Nuclear Medicine and Comprehensive Heart Failure Center, University Hospital Würzburg, Würzburg, Germany
c Institut für Geschichte der Medizin, Christian-Albrechts-Universität Kiel, Kiel, Germany
d Department of Biomedical Imaging, National Cardiovascular and Cerebral Research Center, Suita, Japan
e The James Buchanan Brady Urological Institute and Department of Urology, Johns Hopkins University School of Medicine, Baltimore, MD
*Address correspondence to: Steven P. Rowe, M.D., Ph.D., Division of Nuclear Medicine and Molecular Imaging, The Russell H. Morgan Department of Radiology and Radiological Science, Johns Hopkins University School of Medicine, 601 N. Caroline St., Baltimore, MD 21287.Division of Nuclear Medicine and Molecular ImagingThe Russell H. Morgan Department of Radiology and Radiological ScienceJohns Hopkins University School of Medicine601 N. Caroline St.BaltimoreMD21287
Plan
| Financial Disclosure:Martin G. Pomper is a coinventor on a patent covering 18F-DCFPyL and is entitled to a portion of any licensing fees and royalties generated by this technology. This arrangement has been reviewed and approved by the Johns Hopkins University in accordance with its conflict-of-interest policies. He has also received research funding from Progenics Phamaceuticals, the licensee of 18F-DCFPyL. Michael A. Gorin has served as a consultant to, and has received research funding from, Progenics Phamaceuticals. Kenneth J. Pienta has received research funding from Progenics Phamaceuticals. Steven P. Rowe has received research funding from Progenics Phamaceuticals. The remaining authors declare that they have no relevant financial interests. |
|
| Funding Support:This study was supported by the Prostate Cancer Foundation Young Investigator Award, funds raised by theJames Buchanan Brady Urological Institute, and by theNational Institutes of HealthgrantsCA134675andCA183031. This project has received funding from theEuropean Union's Horizon 2020research and innovation programme under the Marie Sklodowska-Curie grant agreement no.701983. |
© 2018
The Authors. Publié par Elsevier Masson SAS. Tous droits réservés.
Vol 117
P. 18-21 - juillet 2018 Retour au numéro
Article précédent
- Stem Cells for Urinary Incontinence: Functional Differentiation or Cytokine Effects?
- Bradley C. Gill, Daniel Z. Sun, Margot S. Damaser
- Imprudent Utilization of Partial Nephrectomy
- Alice Crane, Chalairat Suk-Ouichai, Jack A. Campbell, Elvis R. Caraballo, Diego Aguilar Palacios, Hajime Tanaka, Steven C. Campbell
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?